4.93
0.07 (1.44%)
| Previous Close | 4.86 |
| Open | 4.83 |
| Volume | 1,201,139 |
| Avg. Volume (3M) | 1,827,214 |
| Market Cap | 688,541,888 |
| Price / Sales | 64.26 |
| Price / Book | 4.21 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Operating Margin (TTM) | -1,222.27% |
| Diluted EPS (TTM) | -1.59 |
| Quarterly Revenue Growth (YOY) | -39.30% |
| Total Debt/Equity (MRQ) | 1.72% |
| Current Ratio (MRQ) | 5.06 |
| Operating Cash Flow (TTM) | -12.32 M |
| Levered Free Cash Flow (TTM) | -52.41 M |
| Return on Assets (TTM) | -18.20% |
| Return on Equity (TTM) | -91.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Aclaris Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.69% |
| % Held by Institutions | 88.24% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOWEN MAXINE | - | - | 0 | 0 |
| HUMPHRIES WILLIAM D. | - | - | 0 | 0 |
| MEHRA ANAND | - | - | 0 | 0 |
| MILANO VINCENT | - | - | 0 | 0 |
| MOLINEAUX CHRISTOPHER P. | - | - | 0 | 0 |
| SCHIFF ANDREW N | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOWEN MAXINE | Director | 05 Jun 2026 | Option execute | 11,580 | - | - |
| MEHRA ANAND | Director | 05 Jun 2026 | Option execute | 11,580 | - | - |
| HUMPHRIES WILLIAM D. | Director | 05 Jun 2026 | Option execute | 11,580 | - | - |
| SCHIFF ANDREW N | Director | 05 Jun 2026 | Option execute | 11,580 | - | - |
| MILANO VINCENT | Director | 05 Jun 2026 | Option execute | 11,580 | - | - |
| MOLINEAUX CHRISTOPHER P. | Director | 05 Jun 2026 | Option execute | 11,580 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |